Publications
Mannix S, Skalicky A, Buse D, Desai P, Sapra S, Ortmeier B, Widnell K, Hareendran A. Measuring the Impact of Migraine for Evaluating Outcomes of Preventive Treatments for Migraine Headaches. Health Qual Life Outcomes. 2016 Oct 6;14(1):143.
Tassorelli C, Diener HC, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ. Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia. 2018 Apr;38(5):815-32.
Hareendran A, Skalicky A, Mannix S, Lavoie S, Desai P, Bayliss M, Thach AV, Mikol DD, Buse DC. Development of a New Tool for Evaluating the Benefit of Preventive Treatments for Migraine on Functional Outcomes – The Migraine Functional Impact Questionnaire (MFIQ). Headache. 2018 Nov;58(10):1612-1628. doi: 10.1111/head.13420. Epub 2018 Oct 30. https://onlinelibrary.wiley.com/doi/epdf/10.1111/head.13420
Kawata AK, Hareendran A, Shaffer S, Mannix S, Thach A, Desai P, Mikol DD, Ortmeier B, Bayliss M, Buse DC. Evaluating the Psychometric Properties of the Migraine Functional Impact Questionnaire (MFIQ). Headache. 2019 Sep;59(8):1253-1269. doi: 10.1111/head.13569. Epub 2019 Jun 5.
Kawata AK, Shah N, Poon JL, Shaffer S, Sapra S, Wilcox TK, Shah S, Tepper SJ, Dodick DW, Lipton RB. Understanding the Migraine Treatment Landscape Prior to Intro of CGRP Inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients Using Preventive Treatment (ATTAIN) Study. Headache.2021 Mar;61(3):438-454.doi:10.1111/head.14053.
Kawata AK, Ladd MK, Lipton RB, Buse DC, Bensink M, Shah S, Hareendran A, Mannix S, Mikol D. Reducing the physical, social, and emotional impact of episodic migraine: Results from erenumab STRIVE and ARISE phase III randomized trials. Headache. 2022 Feb;62(2):159-168. doi: 10.1111/head.14258. Epub 2022 Feb 8. PMID: 35137394.
Posters and Presentations
Hareendran A, Mannix S, Skalicky AM, Widnell K, Corey-Lisle PK, Sapra S. A Qualitative Study of the Functional Impact of Symptoms on Migraine Patients. Presented at EHMTIC – 2014; September 18-21, 2014; Copenhagen, Denmark.
Skalicky AM, Mannix S, Oko-Osi H, Widnell KL, Hareendran A, Corey-Lisle PK, Sapra S. Developing a Conceptual Model of Patients’ Experience of Migraine. Presented at ISOQOL 2014 21st Annual Conference; October 15-18, 2014; Berlin, Germany.
Roberts L, Oko-Osi H, Hareendran A, Mannix S, Desai P, Sapra S. Methods for Addressing Challenges for Evaluating Patient-Reported Outcomes in Clinical Trials of Prophylactic Treatments for Migraines. Presented at AHS 2016; June 9-12, 2016; San Diego, CA, USA.
Skalicky A, Mannix S, Hareendran A, Corey-Lisle P, Widnell K, Buse DC, Desai P, Sapra S. Reflecting Patients’ Perspectives in Measuring Migraine-related Impacts on Functioning: A Qualitative Study with Migraine Patients. Presented at AHS 2016; June 9-12, 2016; San Diego, CA, USA.
Shaffer S, Mannix S, Kawata AK, Thach AV, Desai P, Buse DC, Bayliss M, Sapra S, Mikol DD, Hareendran A. Development and Psychometric Validation of the Migraine Functional Impact Questionnaire (MFIQ): A New Instrument Measuring the Impact of Migraine on Physical, Social, and Emotional Functioning. Presented at AHS 2017; June 8-11, 2017; Boston, MA, USA.
Buse DC, Lipton RB, Mikol DD, Thach AV, Desai P, Picard H, Kubo Y, Hareendran A, Kawata AK. Reducing the Impact of Migraine on Functioning: Results from the STRIVE Trial: A Phase 3, Randomized, Double-Blind Study of Erenumab in Subjects with Episodic Migraine. Presented at IHC 2017; September 7-10, 2017; Vancouver, Canada.
Kawata AK, Shah N, Poon JL, Shaffer S, Sapra S, Mutebi A, Wilcox TK, Tepper SJ, Dodick DW, Lipton RB. Characteristics of Patients Newly Initiating a Preventive Treatment for Migraine: Baseline Data from the Assessment of TolerabiliTy and Effectiveness in MigrAINeurs Using Preventive Treatment (ATTAIN) Study. Presented at IHC 2017; September 7-10, 2017; Vancouver, Canada.